Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial

Richards, J. Scott; Bombardier, Charles H.; Wilson, Catherine S.; Chiodo, Anthony E.; Brooks, Larry; Tate, Denise G.; Temkin, Nancy; Barber, Jason; Heinemann, Allen W.; McCullumsmith, Cheryl B.; Fann, Jesse R.

doi:10.1016/j.apmr.2014.11.024

Cited by 51 publications

(50 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, results from this present study did not find any relationship between nociceptive pain severity on psychosocial aspects of QoL as measured by the SWLS. While venlafaxine XR improved nociceptive pain 27 and also QOL 26 in the larger trial, it does not appear that there is any direct relationship between nociceptive pain severity and QOL across time. QoL is often measured globally, with many different measures used to quantify this construct.…”

Section: Discussionmentioning

confidence: 99%

“…25 In that trial, a reduction in depression severity was associated with improved QoL 26 and in a separate analysis, treatment with venlafaxine XR improved nociceptive pain, but not neuropathic pain. 27 However, the relationship between pain and QoL was not examined. We hypothesized that a reduction in pain would be associated with improved QoL over the course of the trial when accounting for treatment condition.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in pain and quality of life in depressed individuals with spinal cord injury: does type of pain matter?

Richardson

Brooks

Richards

et al. 2016

The Journal of Spinal Cord Medicine

Self Cite

View full text Add to dashboard Cite

Objective: To examine the association of neuropathic and nociceptive pain severity and interference with quality of life (QoL) in persons with spinal cord injury (SCI) who underwent a randomized controlled 12-week trial of an antidepressant to treat depression. A secondary objective was to assess the effect of changes in pain on mobility and physical independence. Design: Multivariable ANCOVA models controlling for relevant demographic covariates, treatment condition, and baseline pain and QoL were used. Setting: Six rehabilitation centers. Participants: Of the 133 persons who were randomized into the trial, 108 provided pain severity and interference ratings through follow-up. Interventions: Not applicable. Outcome Measures: The Satisfaction with Life Scale and the physical and mental component summary scores of the 12-Item Short-Form Health Survey (SF-12). Secondary outcome measures included the mobility and physical independence subscales of the Craig Handicap Assessment and Reporting Technique (CHART). Results: Broadly, few associations between pain and QoL were evident. Results revealed relationships between lower baseline nociceptive pain interference and higher satisfaction with life and mental health-related QoL at 12 weeks. Similarly, lower neuropathic pain interference was associated with change in physical independence, but unrelated to mobility. Conclusions: Pain interference over time may be differentially related to QoL outcomes based on the type of pain following SCI, but overall, there were no extensive relationships between pain and QoL in this sample of depressed persons with SCI.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Changes in pain and quality of life in depressed individuals with spinal cord injury: does type of pain matter?

Richardson

Brooks

Richards

et al. 2016

The Journal of Spinal Cord Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Por lo tanto, las diferencias en la fisiopatología del dolor subyacente serían una razón para la probable ineficacia de la venlafaxina. Sin embargo, es evidente que la mayoría de la bibliografía sobre la venlafaxina y dolor neuropático está centrada en síndromes de dolor neuropático periférico, como la neuropatía diabética (34). En el otro estudio, que no mostró ninguna reducción del dolor con la venlafaxina, Forssell y cols.…”

Section: Discussionunclassified

“…Los resultados de estos estudios se resumen en las Tablas III y IV (24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36).…”

Section: Desarrollounclassified

Venlafaxina en el tratamiento del dolor neuropático

Montero¹

2017

Rev. Soc. Esp. Dolor.

View full text Add to dashboard Cite

Instrucciones de citación para el artículo / Citation instructions for the article:Alcántara Montero Antonio. Venlafaxina en el tratamiento del dolor neuropático / Venlafaxine in the treatment of neuropathic pain. Rev. Soc. Esp. Dolor. 2017. doi: 10.20986/resed.2017.3592/2017 Este es un archivo PDF de un manuscrito inédito que ha sido aceptado para su publicación en la Revista de la Sociedad Española del Dolor. Como un servicio a nuestros clientes estamos proporcionando esta primera versión del manuscrito en estado de prepublicación. El manuscrito será sometido a la corrección de estilo final, composición y revisión de la prueba resultante antes de que se publique en su forma final. Tenga en cuenta que durante el proceso de producción se pueden dar errores lo que podría afectar el contenido final. El copyright y todos los derechos legales que se aplican al artículo pertenecen a la Revista de la Sociedad Española de Dolor. VENLAFAXINA EN EL TRATAMIENTO DEL DOLOR NEUROPÁTICO VENLAFAXINE IN THE TREATMENT OF NEUROPATHIC PAIN A. Alcántara MonteroUnidad del Dolor Hospital Don Benito-Villanueva de la Serena. Don Benito, Badajoz. España CORRESPONDENCIA:Antonio Alcántara Montero a.alcantara.montero@hotmail.com ABSTRACT Introduction: Venlafaxine was the first the first serotonin norepinephrine reuptake

show abstract

“…The authors examined non-neuropathic pain because separate analyses indicated that venlafaxine XR reduced this pain type compared with placebo, rather than SCIrelated neuropathic pain. 7 However, the relationship between effect of the medication on pain and depression needs to be studied further, given that pain interference has been reported to account for 13% to 26% variance in depression in some studies. 8 There was a significant difference in the Maier subscale treatment effect between study sites, suggesting the possibility of latent confounding by study site or staff-related factors.…”

Section: Are the Conclusion Valid?mentioning

confidence: 99%